FcγRI, synonymously also referred to CD64, is a membrane spanning protein of 72 kDa and belongs to the immunoglobulin (Ig) supergene family. It has three extracellular Ig-like domains and is the only receptor that can efficiently bind monomeric IgG and aggregated IgG17. Hence, FcγRI is known to functions as a high-affinity Fcγ receptor where exists other two members FcγRII (CD32) and FcγRIII (CD16), but with low affinity. In humans, FcγRI is constitutively expressed on monocytes/macrophages, myeloid precursors, as well as follicular dendritic cells and its expression can also be induced on polymorphonuclear neutrophils via IFN-γ or G-CSF. Now, FcγRI is considered a great monocyte/macrophage-associated marker, normally used in flow cytometry (FCM) to identify leukemias with myelomonocytic differentiation. GD2 is a kind of disialoganglioside expressed on tumor cells of neuroectodermal origin, including melanoma, glioma and neuroblastoma. Ganglioside GD2 is a sialic acid-containing glycosphingolipid involved in cell attachment to the extracellular matrix. Its expression is highly restricted in normal tissues, principally to the central nervous system, peripheral nerves, skin melanocytes, and mesenchymal stem cells of humans. The relatively specific tumor expression of GD2 makes it a suitable target for clinical therapy with monoclonal antibodies or artificial T cell receptors. Recently, GD2 has been proposed as a marker for some cancer cells and targeting ganglioside GD2 with immunotherapy has resulted in an improved outcome for patients suffering neuroblastoma.